Senti Bio presents the preclinical


SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (SNTI) (“Senti Bio”), a biotechnology company that innovates next-generation cell and gene therapies using its technology proprietary gene circuit platform, today announced a poster presentation at the 64th Annual Meeting of the American Society of Hematology (ASH), to be held December 10-13, 2022 in New Orleans, LA .

Information on the presentation of the ASH:
Date and time: Saturday, December 10, 2022, 5:30 p.m. – 7:30 p.m. CST
Title: SENTI-202, a selective, ready-to-use, preclinical CAR-NK cell therapy with CAR activating CD33 and/or FLT3, protection of healthy cells against endomucin-inhibiting CAR (EMCN) and timed-release IL-15 for hematological malignancies, including AML
Session name: 703. Cellular immunotherapies: basic and translational: poster I
Abstract number: 1978
Location: Ernest N. Morial Convention Center, Hall D

Following the presentation, a copy of the poster will be available on the Scientific presentations and publications page on the Senti Bio website.

About Senti Bio

Our mission is to create a new generation of smarter medicines that outsmart complex diseases using new and unprecedented approaches. To do this, we are building a synthetic biology platform that could allow us to program next-generation cell and gene therapies with what we call Gene Circuits. These genetic circuits, which are created from novel and unique combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to their cellular environments. Our goal is to design genetic circuits to improve the intelligence of cell and gene therapies to improve their therapeutic efficacy, precision and durability against a wide range of diseases that conventional drugs do not easily treat.

Our synthetic biology platform uses ready-to-use chimeric antigen receptor (CAR-NK) natural killer cells, equipped with Gene Circuit technologies, to target particularly challenging indications in liquid and solid tumor oncology. Our lead development candidate is SENTI-202 for the treatment of acute myeloid leukemia (AML). Other CAR-NK programs include SENTI-301 for the treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the treatment of CEACAM5-expressing solid tumors, including colorectal cancer (CRC). We have also demonstrated the breadth of our genetic circuits in other modalities and diseases outside of oncology and have partnered with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.

Forward-looking statements

This press release and this document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are generally identified by the words “believe”, “could”, “predict”, “continue”, “ongoing”, “project”, “expect”, “anticipate”, “estimate”, ” intend, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “should”, “would”, “will”, “will continue”, “probably result”, “expect”, “seek”, “target” and similar expressions that predict or indicate future events or trends or are not statements of historical matters. Forward-looking statements are predictions, projections and other statements regarding future events that are based on management’s current expectations and Senti Bio’s assumptions, whether or not identified herein, and, by therefore, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, upcoming poster session, as well as related presentations; statements regarding upcoming presentation and availability of presentation information, Senti Bio’s research and development activities, including the creation of new cell and gene therapies; as well as statements about the attributes and potential benefits of Senti Bio’s platform product candidates and technology. These forward-looking statements are provided for informational purposes only and are not intended to serve and should not be relied upon by any investor as a guarantee, assurance, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from the assumptions. Many actual events and circumstances are beyond Senti Bio’s control. Many factors could cause actual future results to differ materially from the forward-looking statements contained herein, including, but not limited to: (i) changes in domestic and foreign affairs, market, financial conditions , political and legal, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance among competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and the changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks related the uncertainty of any projected financial information concerning Senti Bio, (vi) risks related to uncertainty as to the timing or results of preclinical studies of Senti Bio, IND filings and start-up GMP manufacturing activities, (vii) Senti Bio’s reliance on third parties in connection with preclinical sts and enabling IND studies, the filing of IND and GMP manufacturing construction and start-up activities, (viii) risks related to delays and other impacts of the COVID-19 pandemic, and (ix) the success of all future research and development efforts of Senti Organic. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s registration statement on Form S-1 (File No. 333-267390), filed with the SEC on September 12, 2022, and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements contained herein. There may be additional risks that Senti Bio is not currently aware of, or that Senti Bio currently believes are not material, that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s valuations to change. Except as required by law, Senti Bio undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Availability of other information about Senti Biosciences, Inc.

For more information, please visit Senti Bio’s website at or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company’s website (, including, but not limited to, company disclosures, presentations to investors and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. Information that we post on our website or on Twitter or LinkedIn may be considered material information. Accordingly, we encourage investors, the media and other interested persons to regularly review the information we post there. The content of our website or social media should not be taken as incorporated by reference in any filing under the Securities Act 1933, as amended.

More information on
Follow us on Linkedin: Senti Biosciences
Follow us on Twitter: @SentiBio



About Author

Comments are closed.